The pharmacotherapy of Takayasu arteritis (TAK) with disease-modifying anti-rheumatic
drugs (DMARDs) is an evolving area. A systematic review of Scopus, Web of Science …

Takayasu arteritis is an idiopathic granulomatous vasculitis of the aorta and its main
branches and it constitutes one of the more common vasculitides in children. Inflammation …

Assessment of the pattern and extent of arterial involvement and measurement of current
disease activity are essential for the management of Takayasu arteritis (TA). Since there is …

Although outcomes in Takayasu arteritis (TAK) are improving, diagnosis is typically delayed
and significant arterial injury accrues. While wider use of non-invasive imaging is impacting …

Takayasu arteritis (TA) is a rare disease affecting chiefly young women, although it can affect
both men and women and persons of many different ethnicities. TA carries a high morbidity …

More than 10 disease-modifying therapies (DMT) are approved by the European Medicines
Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of multiple …

Background Takayasu arteritis (TA) is a rare, systemic, inflammatory vasculitis of
granulomatous nature, and still of unknown etiology. It mainly involves the aorta and its …

Takayasu arteritis (TA) is a challenging large vessel vasculitis to treat. Distinguishing
disease activity from vascular damage is difficult, often relying on clinician judgement aided …

Takayasu arteritis (TAK) is a challenging chronic, granulomatous, large-vessel systemic
vasculitis, mostly due to difficulties in early diagnosis and assessing actual disease activity …

Objectives. Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) affect individuals
older than 50 years of age and corticosteroids are the mainstay of treatment. The aim of our …